Chamath Palihapitiya Reenters SPAC Market: Previous 18 Deals Show Average Loss of 14%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy CLOV?
Source: Benzinga
New SPAC Launch: Chamath Palihapitiya has filed for a new SPAC, American Exceptionalism Acquisition Corp A (ticker AEAC), aiming to raise $250 million and invest in sectors like AI, clean energy, U.S. defense, or decentralized finance.
Investor Sentiment: Despite launching the new SPAC, investor sentiment remains cautious due to poor past returns from his previous SPAC deals, with a recent poll indicating that 70.7% of respondents were against him launching another SPAC.
Performance Overview: Palihapitiya has been involved in 18 SPACs, with an average return of -13.98%. His own SPACs have performed worse, averaging -26.24%, while PIPE deals he financed yielded a modest +1.34%.
Future Prospects: The new SPAC's structure includes milestone-based vesting for founder shares, which may encourage long-term investment. However, given past performance, interest from investors might be limited despite Palihapitiya's connections in Silicon Valley and the White House.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.020
Low
3.00
Averages
3.35
High
3.70
Current: 2.020
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clover Health Stock Declines Due to Medicare Proposal
- Medicare Payment Rate Impact: The Trump administration's CMS proposed nearly flat MA payment rates for 2027, with a mere 0.09% year-over-year increase, significantly below Wall Street's 4%-6% growth expectations, which could lead to slower revenue growth per member for Clover, forcing the company to either absorb higher medical costs or cut supplemental benefits, thereby impacting its competitiveness in the market.
- Pressure from UnitedHealth Earnings: UnitedHealth Group reported a sharp decline in adjusted EPS and a medical care ratio near 89%, with 2026 sales guidance falling short of expectations, indicating rising utilization and thinner margins in the MA sector, which raises concerns about Clover's profitability as investors perceive it as having less capacity to absorb costs compared to larger players.
- Bearish Stock Trend: Clover's stock is currently trading 7.2% below its 20-day simple moving average and 14.4% below its 100-day SMA, with a 48.70% decrease over the past 12 months, reflecting ongoing challenges, while the RSI is neutral and the MACD indicates mixed momentum for the stock.
- Upcoming Earnings Report Outlook: Investors are looking forward to the earnings report scheduled for February 26, with an EPS estimate of a 7-cent loss and revenue projected at $469.23 million, up from $336.96 million year-over-year, while analysts maintain a hold rating with an average price target of $6.02, indicating cautious sentiment regarding Clover's future performance.
See More
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
- Retail Sales Surge: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, indicating a potential rebound in consumer spending that could positively impact economic recovery.
- Tech Stock Decline: Information technology stocks fell by 1.3% on Wednesday, reflecting market concerns over the tech sector, which may affect investor confidence and lead to capital outflows.
- High-Risk Stock Surge: High Roller Technologies, Inc. (NYSE:ROLR) shares skyrocketed 289% to $13.64 after announcing a binding Letter of Intent with Crypto.com to launch an event-based prediction markets product in the U.S., demonstrating strong market demand for innovative offerings.
- IPO Impact: Briacell Therapeutics Corp. (NASDAQ:BCTX) priced its $30 million public offering at $5.59 per unit, leading to a 53% drop in its stock price to $5.09, reflecting market sensitivity to financing activities.
See More
Clover Health (CLOV) Expects First Full-Year GAAP Profitability with 53% Membership Growth
- Profitability Expectations: Clover Health anticipates achieving its first full-year GAAP net income this year, marking a significant milestone in its profitability journey that could attract more investor interest.
- Significant Membership Growth: The company reported a rise in Medicare Advantage membership to 153,000 during the Annual Enrollment Period, reflecting a 53% increase, showcasing the effectiveness of Clover Assistant in enhancing healthcare delivery.
- Strong Short-Term Momentum: Clover Health's stock is currently trading 12.8% above its 20-day SMA and 10.4% above its 50-day SMA, indicating positive short-term market sentiment that may drive further price increases.
- Technical Indicator Analysis: Despite a 23.41% decline in share price over the past 12 months, the RSI is in neutral territory while the MACD is above its signal line, suggesting mixed momentum but overall technical indicators lean towards a positive outlook, potentially providing buying opportunities for investors.
See More
Clover Health (CLOV) Reports 53% Membership Growth for 2026, Shares Up 11%
- Significant Membership Growth: Clover Health's Medicare Advantage plans saw a 53% increase in enrollees for the 2026 plan year, bringing total membership to approximately 153,000 as of January 1, with over 97% opting for its flagship PPO plan, indicating strong market appeal.
- Optimistic Profit Outlook: The company anticipates achieving its first-ever GAAP net income profitability in 2026, driven by cost optimization efforts and the 2026 CMS final rate update, suggesting an improving financial health.
- Positive CEO Outlook: CEO Andrew Toy remarked that these dynamics will create compounding earnings and margin expansion, positioning Clover to deliver GAAP net income profitability in 2026, reflecting confidence in future growth.
- Market Reaction: Following the disclosure of membership growth and profit expectations, Clover Health's shares rose approximately 11%, indicating investor optimism about its future performance and further validating its business model.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
Clover Health Reports 53% Medicare Advantage Growth, Aiming for GAAP Net Income Profitability in 2026
- Significant Membership Growth: Clover achieved a 53% increase in Medicare Advantage membership for the 2026 plan year, totaling approximately 153,000 members, demonstrating robust growth and strong retention in core markets.
- Optimistic Profit Outlook: Clover expects to achieve its first-ever GAAP net income profitability in 2026, driven by strong cohort economics and ongoing SG&A optimization, indicating a significant improvement in profitability.
- Stable Member Retention: Clover maintained over 95% annual enrollment member retention in 2026, reinforcing the stability of its membership base and enhancing its appeal in a competitive market.
- Industry-Leading Quality: Over 97% of Clover's members are enrolled in its flagship PPO plan, which has ranked #1 nationally on core HEDIS quality measures for the second consecutive year, further validating Clover's clinical and economic performance strengths.
See More
Clover Health Stock Declines Due to Medicare Proposal
- Medicare Payment Rate Impact: The Trump administration's CMS proposed nearly flat MA payment rates for 2027, with a mere 0.09% year-over-year increase, significantly below Wall Street's 4%-6% growth expectations, which could lead to slower revenue growth per member for Clover, forcing the company to either absorb higher medical costs or cut supplemental benefits, thereby impacting its competitiveness in the market.
- Pressure from UnitedHealth Earnings: UnitedHealth Group reported a sharp decline in adjusted EPS and a medical care ratio near 89%, with 2026 sales guidance falling short of expectations, indicating rising utilization and thinner margins in the MA sector, which raises concerns about Clover's profitability as investors perceive it as having less capacity to absorb costs compared to larger players.
- Bearish Stock Trend: Clover's stock is currently trading 7.2% below its 20-day simple moving average and 14.4% below its 100-day SMA, with a 48.70% decrease over the past 12 months, reflecting ongoing challenges, while the RSI is neutral and the MACD indicates mixed momentum for the stock.
- Upcoming Earnings Report Outlook: Investors are looking forward to the earnings report scheduled for February 26, with an EPS estimate of a 7-cent loss and revenue projected at $469.23 million, up from $336.96 million year-over-year, while analysts maintain a hold rating with an average price target of $6.02, indicating cautious sentiment regarding Clover's future performance.
See More
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
- Retail Sales Surge: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, indicating a potential rebound in consumer spending that could positively impact economic recovery.
- Tech Stock Decline: Information technology stocks fell by 1.3% on Wednesday, reflecting market concerns over the tech sector, which may affect investor confidence and lead to capital outflows.
- High-Risk Stock Surge: High Roller Technologies, Inc. (NYSE:ROLR) shares skyrocketed 289% to $13.64 after announcing a binding Letter of Intent with Crypto.com to launch an event-based prediction markets product in the U.S., demonstrating strong market demand for innovative offerings.
- IPO Impact: Briacell Therapeutics Corp. (NASDAQ:BCTX) priced its $30 million public offering at $5.59 per unit, leading to a 53% drop in its stock price to $5.09, reflecting market sensitivity to financing activities.
See More
Clover Health (CLOV) Expects First Full-Year GAAP Profitability with 53% Membership Growth
- Profitability Expectations: Clover Health anticipates achieving its first full-year GAAP net income this year, marking a significant milestone in its profitability journey that could attract more investor interest.
- Significant Membership Growth: The company reported a rise in Medicare Advantage membership to 153,000 during the Annual Enrollment Period, reflecting a 53% increase, showcasing the effectiveness of Clover Assistant in enhancing healthcare delivery.
- Strong Short-Term Momentum: Clover Health's stock is currently trading 12.8% above its 20-day SMA and 10.4% above its 50-day SMA, indicating positive short-term market sentiment that may drive further price increases.
- Technical Indicator Analysis: Despite a 23.41% decline in share price over the past 12 months, the RSI is in neutral territory while the MACD is above its signal line, suggesting mixed momentum but overall technical indicators lean towards a positive outlook, potentially providing buying opportunities for investors.
See More
Clover Health (CLOV) Reports 53% Membership Growth for 2026, Shares Up 11%
- Significant Membership Growth: Clover Health's Medicare Advantage plans saw a 53% increase in enrollees for the 2026 plan year, bringing total membership to approximately 153,000 as of January 1, with over 97% opting for its flagship PPO plan, indicating strong market appeal.
- Optimistic Profit Outlook: The company anticipates achieving its first-ever GAAP net income profitability in 2026, driven by cost optimization efforts and the 2026 CMS final rate update, suggesting an improving financial health.
- Positive CEO Outlook: CEO Andrew Toy remarked that these dynamics will create compounding earnings and margin expansion, positioning Clover to deliver GAAP net income profitability in 2026, reflecting confidence in future growth.
- Market Reaction: Following the disclosure of membership growth and profit expectations, Clover Health's shares rose approximately 11%, indicating investor optimism about its future performance and further validating its business model.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
Clover Health Reports 53% Medicare Advantage Growth, Aiming for GAAP Net Income Profitability in 2026
- Significant Membership Growth: Clover achieved a 53% increase in Medicare Advantage membership for the 2026 plan year, totaling approximately 153,000 members, demonstrating robust growth and strong retention in core markets.
- Optimistic Profit Outlook: Clover expects to achieve its first-ever GAAP net income profitability in 2026, driven by strong cohort economics and ongoing SG&A optimization, indicating a significant improvement in profitability.
- Stable Member Retention: Clover maintained over 95% annual enrollment member retention in 2026, reinforcing the stability of its membership base and enhancing its appeal in a competitive market.
- Industry-Leading Quality: Over 97% of Clover's members are enrolled in its flagship PPO plan, which has ranked #1 nationally on core HEDIS quality measures for the second consecutive year, further validating Clover's clinical and economic performance strengths.
See More
